This trial has been completed.

Conditions meningitis, meningococcal meningitis, meningococcal infections
Treatment meningococcal (groups a, c, y and w 135) polysaccharide diphtheria toxoid conjugate
Phase phase 4
Sponsor Sanofi Pasteur, a Sanofi Company
Start date October 2015
End date May 2016
Trial size 60 participants
Trial identifier NCT02591290, MTA89 (EFC14375), U1111-1174-4291


The aim of this study is to collect further information regarding an increase immune response of SP284 after an additional dose in Japanese subjects.

Primary Objective:

- To evaluate and describe the immune responses to meningococcal antigens (serogroups A,C, Y and W-135) at 28 days following each vaccination with SP284 vaccine in subjects 20 through 55 years of age.

Other Pre-specified objective:

- To describe the safety in terms of immediate systemic adverse events, solicited reactions, unsolicited non-serious adverse events, and serious adverse events (SAEs) following receipt of each dose of SP284 vaccine in persons 20 through 55 years of age.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Primary purpose prevention
Masking no masking
Participants will receive a 2 dose series of the study vaccine at 8 week interval
meningococcal (groups a, c, y and w 135) polysaccharide diphtheria toxoid conjugate SP284; Menactra®
0.5 mL, Intramuscular (2 doses at 8 weeks interval)

Primary Outcomes

Number of participants with meningococcal serogroups A, C, Y, and W-135 antibody titers ≥ 1:128 following each vaccination with Menactra vaccine
time frame: Up to Day 35 post each vaccination

Eligibility Criteria

All participants from 20 years up to 55 years old.

Inclusion Criteria: - Aged 20 through 55 years on the day of inclusion - Informed consent form has been signed and dated by the subject - Able to attend all scheduled visits and to comply with all trial procedures - For female subjects who have childbearing potential, use of an effective method of contraception from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination - a) "20 through 55 years" means from the day of the 20th birthday to the day before the 56th birthday. - b) To be considered to be not of childbearing potential, a woman must either have undergone surgical sterilization (hysterectomy or bilateral tubal ligation) or be postmenopausal (at least one year without menses) at the time of vaccination. Effective methods of contraception include oral contraception (pill), intrauterine device, diaphragm or condoms used with sponge, contraceptive foam or cream, hormonal implants, transdermal patch, or parenteral contraception. Exclusion Criteria: - Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion - History of meningococcal diseases, confirmed either clinically, serologically, or microbiologically - Known systemic hypersensitivity to any of the vaccine components, or history of a life threatening reaction to a vaccine containing the same substances of the study vaccine - Known or suspected congenital or current/ previous acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) - Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial inclusion - Planned participation in another clinical trial during the present trial period - Receipt of immune globulins, blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response - Receipt of any vaccine within the four weeks preceding the trial vaccination, except for influenza vaccination, which may be received at least two weeks before the study vaccine - Planned receipt of any vaccine during the trial period - Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or Human Immunodeficiency Virus infection - Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination) - Known thrombocytopenia, contraindicating intramuscular (IM) vaccination - Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination - Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily - Current alcohol abuse or drug addiction - Identified as employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family member (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator - Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine - At high risk for meningococcal infection during the trial - Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination. A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided - Received oral or injected antibiotic therapy within the 72 hours prior to blood draw (Visit 1) - History of Guillain-Barré Syndrome (GBS).

Additional Information

Official title Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects
Description All subjects will receive a 2-dose series of the study vaccine at 8-week interval and will be monitored for safety and assessed for immunogenicity at baseline (pre-vaccination), at 28 to 35 days post-1st and 2nd vaccination, respectively.
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Sanofi.